SCHEMBL717060

SCHEMBL717060

Cc1ccc(N)cc1-c1nc(-c2cccnc2)cs1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 12/20 0.66
AXL P30530 1/20 0.61
PBRM1 Q86U86 1/20 0.61
MKNK1 Q9BUB5 1/20 0.61
MKNK2 Q9HBH9 1/20 0.61
RAB9A P51151 4/20 0.58
NPC1 O15118 3/20 0.58
CYP17A1 P05093 1/20 0.57
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP1A1 P04798 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP1B1 Q16678 1/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MEN1 O00255 1/20 0.52
CASP3 P42574 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27922656 0.87 CYP19A1 (0.64) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL207818 0.87 CYP19A1 (0.64) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL719078 0.85 CYP19A1 (0.61) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL19051355 0.82 CYP19A1 (0.79) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL1439800 0.80 AXL (0.56) CYP19A1AXLMKNK1MKNK2ALDH1A1
SCHEMBL30714540 0.80 AXL (0.56) CYP19A1AXLMKNK1MKNK2ALDH1A1
SCHEMBL17014792 0.80 CYP19A1 (0.70) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL6798787 0.79 CYP19A1 (0.72) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL5001904 0.78 RAB9A (0.48) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL1096303 0.78 GAA (0.79) RAB9ANPC1ALDH1A1MEN1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4726486-B2 2011-07-20 JP claimed
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders AB SCIENCE 2008-10-16 US claimed
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 US claimed
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2005-10-27 US claimed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP claimed
WO-2004098612-A2 CALCITRIOL ANALOGS OF USES THEREOF AB SCIENCE (FR) 2004-11-18 WO claimed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US claimed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO claimed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
US-8450302-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2013-05-28 US disclosed
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2012-03-01 US disclosed
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2011-08-18 US disclosed
WO-2004098612-A2 CALCITRIOL ANALOGS OF USES THEREOF AB SCIENCE (FR) 2004-11-18 WO disclosed
WO-2004096225-A2 USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA AB SCIENCE (FR) 2004-11-11 WO disclosed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US disclosed
WO-2004026311-A2 USE OF SPECIFIC INHIBITORS OF TYROSINE KINASES FOR IMMUNOMODULATION INSTITUT GUSTAVE ROUSSY (IGR) (FR) 2004-04-01 WO disclosed
WO-2004020500-A1 A GEMINALLY DISUBSTITUTED OLEFIN-CARBON MONOXIDE-ETHYLENE POLYMER USEFUL AS A POLYVINYL CHLORIDE PLASTICIZER AND A METHOD OF MAKING THE SAME EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2004-03-11 WO disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053186-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, CHUK, MAP3K2 CYP19A1 771/4885AXL 438/4885PBRM1 3723/4885
US-20110201620-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS KIT, ABL1, MUSK CYP19A1 3737/4885AXL 269/4885PBRM1 2292/4885
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. KIT, MAP3K2, CMA1 CYP19A1 1663/4885AXL 919/4885PBRM1 3504/4885
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes KIT, CPA3, CMA1 CYP19A1 2500/4885AXL 2137/4885PBRM1 4724/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B CYP19A1 928/4885AXL 656/4885PBRM1 3591/4885
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors KIT, CHUK, MAP3K2 CYP19A1 746/4885AXL 400/4885PBRM1 3588/4885
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders KIT, MAP3K1, MAP3K6 CYP19A1 696/4885AXL 536/4885PBRM1 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.